Omeros (NASDAQ:OMER) Downgraded to Sell Rating by StockNews.com

Omeros (NASDAQ:OMER - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Wednesday.

Other equities research analysts also recently issued research reports about the company. D. Boral Capital restated a "buy" rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday, April 1st. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $22.50.

Omeros Trading Up 14.8 %

NASDAQ OMER traded up $0.87 on Wednesday, hitting $6.73. 826,047 shares of the company were exchanged, compared to its average volume of 571,532. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60. The firm has a 50 day moving average of $8.21 and a two-hundred day moving average of $7.77. The company has a market cap of $390.77 million, a P/E ratio of -2.91 and a beta of 2.35.

Omeros (NASDAQ:OMER - Get Free Report) last announced its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.08. During the same quarter last year, the business earned ($0.15) EPS. Research analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omeros

Large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 1,110 shares during the period. Truvestments Capital LLC grew its position in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 1,669 shares during the period. Tower Research Capital LLC TRC increased its position in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 1,972 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Omeros by 2.0% in the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock valued at $1,190,000 after acquiring an additional 2,317 shares during the period. Finally, Cerity Partners LLC lifted its stake in shares of Omeros by 9.9% during the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 2,600 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.